This summer, CCADD welcomes two undergraduate interns, Hyunji Park and Dayoon Lee, for the 2026 Summer Internship Program.

Hyunji Park is an undergraduate student in Bio Nano Engineering at Hanyang University, where she is also pursuing interdisciplinary studies in Pharmaceutical Science and Intelligent Robotics. Her academic interests lie at the intersection of life sciences, artificial intelligence, and digital healthcare, with a particular focus on applying data-driven approaches to drug development and clinical research. She has gained interdisciplinary research experience in molecular biology, proteomics, and biomedical data analysis through projects involving DNA cloning, urine exosome-based biomarker discovery for the early diagnosis of preeclampsia, and machine learning-based proteomic data analysis using OmicLearn. These experiences have strengthened her interest in integrating experimental biology with computational approaches and were recognized with research awards from Hanyang University and the Women's Bioscience Forum. Through the CCADD internship, she hopes to contribute to interdisciplinary research while expanding her understanding of AI-driven drug development and computational approaches for evaluating drug efficacy and safety. She aims to further develop her expertise in biomedical data analysis, translational research, and regulatory science, ultimately contributing to safer and more effective drug development.

Dayoon Lee is an undergraduate student at Seoul National University, where she studies Animal Biotechnology alongside an interdisciplinary major in Artificial Intelligence. Her academic interests lie at the intersection of biomedical science and computational research, particularly in understanding how data-driven methods can support safer and more effective drug development. She has gained interdisciplinary research experience in CAR-T cell engineering, toxicology, and medical AI, including a 3D CT-based Vision-Language Model project conducted in collaboration with clinicians. Through the CCADD internship, she hopes to combine her biological with computational approaches and explore how AI and biomedical data can contribute to evaluating drug efficacy and safety. She aims to strengthen her expertise in data-driven drug development and regulatory science through participation in CCADD’s ongoing research projects.

CCADD warmly welcomes the two interns and hopes that the program will provide them with meaningful opportunities to expand their research experience, deepen their understanding of drug development, and pursue their scientific interests with curiosity and independence.

Researchers, clinicians, and engineers working at the crossroads of artificial intelligence and medicine got together once again this summer, and CCADD (Prof. Howard, David, Seeun) was there to join them. The occasion was the Conference on Health, Inference, and Learning (CHIL) 2026, a three-day gathering hosted in Seattle, Washington from June 28th through 30th.

Among a handful of research groups that were extended an invitation to the conference, Prof. Howard traveled together with his team Dr. David and Seeun. What made the trip especially meaningful this year was the publication of a paper from the lab, "Generation of Biingual Synthetic Clinical Notes for Realistic Data Augmentation," which the team unveiled to the community at the conference. Standing beside their poster, they walked visitors through the motivation and findings of the work, answering questions from curious attendees.

This year marked the seventh gathering of CHIL, jointly hosted by Sage Bionetworks and Seattle Children's Research Institute and hosted at the Institute's B. Wayne Hughes Building. As always, the program spanned a broad cross-section of issues shaping AI's role in healthcare. The conference opened with a keynote from Dr. Chris Longhurst, CEO of Seattle Children's, who spoke on "Evidence-based Medicine in the AI Era" and made the case for grounding AI adoption in real clinical implementation rather than hype. Dr. Pang Wei Koh followed with an invited talk on reinforcement learning approaches for deep research, and Dr. Jessilyn Dunn later delivered a keynote on wearable technology for disease detection titled "The Digital Physiome." A track devoted entirely to mental health also drew particular attention, weaving together talks on evaluating harm in AI safety, personalizing psychotherapy through language models, and building governance frameworks informed by practitioners, which were all capped off with a lively panel discussion.

For the team, the days in Seattle offered far more than a chance to share their research. They came away with new perspectives, new connections, and a renewed sense of how much further this field still has to grow.

The research article entitled “Prephase Steroid Treatment before Remission Induction Chemotherapy in Patients with Pediatric Acute Lymphoblastic Leukemia Using Common Data Model-Based Real-World Data: A Retrospective Observational Study”¹, which was first-authored by the former CCADD graduate,Yoona Choi, and co-authored by the members of CCADD  has been cited in the lastest haematology guidelines on the diagnosis and managemet of tumour lysis syndrome² published by the British Society for Haematology. Moreover, the study was cited in a recent review article published in the New England Journal of Medicine (NEJM)³ detailing the epidemiology and pathophysiology of tumor lysis syndrome.

The British Society for Haematology produces up-to-date evidence-based guidelines on the diagnosis and treatment of haematological disease, while The New England Journal of Medicine is one of the prominent journals of new medical knowledge and clinical best practicies worldwide (Impact Factor 78.5).

This recognition highlights the clinical significance of our study in advancing evidence-based practice for pediatric acute lymphoblastic leukemia. CCADD takes pride in producing research that informs medical decision-making, and will continue efforts to deliver impactful studies.

1_Choi Y, Kim BK, Won JH, Yoo JW, Choi W, Jung S, Kim JY, Choi IY, Chung NG, Lee JW, Choi JY, Kang HJ, Lee H. Prephase steroid treatment before remission induction chemotherapy in patients with pediatric acute lymphoblastic leukemia using common data model-based real-world data: a retrospective observational study. Clin Epidemiol. 2024 Apr 22;16:293-304. doi:10.2147/CLEP.S454263. PMID:38681782; PMCID:PMC11049150.

2_Chan YLT, El-Sharkawi D, Shah P, Chanouzas D, O’Connor D, Marks SD, et al. British Society for Haematology updated guidelines for the diagnosis and management of tumour lysis syndrome in adults and children with haematological malignancies: a focus on patient safety. Br J Haematol. 2025;00:1-11. doi:10.1111/bjh.70092.

3_Bociek RG, Lunning M. Tumor lysis syndrome. N Engl J Med. 2025 Sep 18;393(11):1104-1116. doi:10.1056/NEJMra2300923. PMID:40961427.

Soyoung Park is an undergraduate researcher at CCADD after completing the 2025 Summer Internship program. She is a double major in Material Science and Engineering and Industrial and Data Engineering at Hongik University. During her undergraduate years, she was able to combine a strong foundation in engineering with advanced data analysis skills. During the internship, she participated in the research projects, where she gained experience in causality assessment for drug safety and developed a broader understanding of the overall drug development process. Building on these experiences, she is now exploring AI-driven approaches to drug development, with a particular interest in drug–drug interaction prediction and explainable machine learning, aiming to contribute to the advancement of safer and more effective drug development.

This winter, CCADD welcomes six interns- Minsol Kim, Suhyun An, SeoYoon Jang, Seeun Park, Yura Choi and Nayoung Ku -  for the 2025 Winter Internship Program.

Minsol Kim is majoring in veterinary medicine at Seoul National University. She is interested in exploring the application of domain knowledge in the process of AI model development by utilizing her knowledge of pharmacology, toxicology, and physiology. Her goal is to build a solid foundation in AI and gain hands-on experience analyzing clinical data and investigating the drug development process. Through the 2025 CCADD winter internship program, she aims to explore potential career paths in the field of drug discovery.

Suhyun An is a student majoring in Stem Cell and Regenerative Biotechnology at Konkuk University. She previously worked as an undergraduate researcher in the Immunopharmacology Laboratory at Seoul National University College of Medicine, where she studied drug toxicity. Her current research interests include Drug-Drug Interactions (DDIs) and drug repurposing using artificial intelligence (AI). Her previous training primarily involved wet lab research. The CCADD internship will allow her to gain experience in data science applied to drug development, which will serve as a critical foundation for achieving her future research goals.

SeoYoon Jang is majoring in Systems Biotechnology at Chung-Ang University. She has a keen interest in AI and data science, which led her to complete the 2024 Boostcourse <DATA SCIENCE PROJECTS> coaching study program. Subsequently, she developed an interest in drug delivery and interned at the Lab of Drug Delivery and Cell Therapy at Sungkyunkwan University School of Medicine. Her growing passion for integrating AI into drug development led her to a winter internship at the CCADD. Through this internship, she aims to gain proficiency in data analysis tools and deepen her domain knowledge, with the goal of becoming a researcher specializing in AI-driven drug development.

Seeun Park is a senior at Yonsei University, double majoring in Biotechnology and Public Administration. She is willing to explore clinical pharmacology and regulatory science during this winter internship program. With passion in healthcare and safety, she focuses on gaining more experience and knowledge on artificial intelligence for clinical drug development and more specifically epigenetic study and policy analysis in Korea. It is her goal to work on expertise for the improvement of disease prevention and control.

Yura Choi is an undergraduate student in the Department of Chemistry at Kyung Hee University. She is passionate about AI-driven drug development, applying data science to pharmaceutical research. Through the LAIDD program, she has gained valuable insights into how AI can be applied to drug development. She aims to contribute to drug development and explore innovative therapeutic modalities by leveraging AI-driven data analysis. Currently, she is participating in the CCADD winter internship to strengthen her AI and data science expertise and deepen her understanding of research in drug development.

Nayoung Ku is an undergraduate in life science and AI convergence at Handong Global University. She previously earned a Bachelor’s degree in psychology at the National Institute of Lifelong Education by Examination for Self-Education. Nowadays, Nayoung mainly develops prediction modelling and optimization algorithms with various datasets. She had been a research assistant at Biodata Laboratory, Handong Global University, focusing on cancer diagnostic machine learning models using tumour-educated platelet (TEP) RNA-seq data for a year. Recently, she did a capstone project on NLP for an ovarian cancer diagnostic model using TEP RNA-seq pre-processed data, which showed her creativity in analytic approach. She received the Daewoong Pharmaceutical CEO Award at the JUMP AI 2024 Drug Discovery Competition, sponsored by the Korea Pharmaceutical and Bio-Pharma Manufacturers Association. In the competition, Nayoung and her team developed an advanced multi- perceptron to predict IC50 values for IRAK4 inhibitors by applying novel and strategic approaches to accelerate drug discovery processes. With her enthusiasm for enhancing the efficiency of drug discovery, she participates in this internship to experience real-world clinical data and its analysis, like electronic medical records. With a heart of admiration, she is yearning to learn the extraordinary methodology of CCADD. 

We hope that during their winter internship, they will build confidence in their area of expertise, develop independent learning skills to explore new knowledge, and dedicate their enthusiasm to gaining a comprehensive understanding of drug development and regulatory science throughout these two months.

CCADD members attended the 2025 Spring Conference of the Korean Society of Medical Informatics (KOSMI), held from June 22 to 24 at the Busan Port International Exhibition & Convention Center. Under the theme “AI and Human Collaboration in the Age of Generative AI,” the conference brought together experts from medicine, engineering, law, and industry to discuss the latest developments and practical applications in medical informatics.

Key topics included strategies to automate workflows involving electronic medical records (EMRs) , such as methods using large language models (LLMs), strategies for utilizing MyData in healthcare, integration of genomic and spatial biology data for precision medicine, the potential of quantum computing in medicine, and AI-driven clinical prediction and decision support systems (CDSS).

In the keynote speech, Prof. Adrian Zai of UMass Chan Medical School delivered a presentation titled “Steering the Future of Medicine: Human-Centered AI in the Generative Age.” He emphasized the importance of moving beyond what AI can do, toward how its impact should be directed in clinical settings. He highlighted human-centered design, ethical oversight, and global collaboration as essential to ensuring AI truly supports care delivery.

Dr. Yoona Choi, a former member of CCADD and now a research professor at Seoul National University Hospital's Child Cancer and Rare Disease Project, presented her work on developing an LLM-based computable phenotype for pediatric lymphoma subtypes. The model leverages structured and unstructured EMR data—such as pathology reports and genetic test results—to improve classification accuracy based on real-world clinical data.

Prof. Howard Lee, Founding Director of CCADD and CEO of the digital health startup PMATCH, introduced PillTalk, a mobile app that allows patients to independently check drug–drug interactions using public data made available by the Ministry of Food and Drug Safety. The app provides AI-powered, accessible information to help patients make safer medication decisions. Prof. Lee emphasized that public pharmaceutical datasets can be transformed into practical, patient-centered tools to enhance medication safety.

Through this conference, CCADD members were able to reflect on the essential role of interdisciplinary collaboration and responsible innovation in leveraging digital technologies to advance patient-centered care.

Seeun Park is a Master’s student at the Department of Molecular Medicine and Biopharmaceutical Science (MMBS), Graduate School of Convergence Science, Seoul National University. She previously worked as an undergraduate researcher at CCADD after completing the 2024 Winter Internship Program. She majored in Bioengineering at Yonsei University. She was able to gain knowledge and hands-on experience on artificial intelligence for clinical drug development by the project “Improving the Generalizability of Natural Language Process Models to Extract Drug Safety Information from Clinical Notes”. With passion in healthcare and safety, she focuses on exploring clinical pharmacology and regulatory science more specifically Real-World Data (RWD) and policy analysis in Korea. It is her goal to work on expertise for the improvement of disease prevention and control.

On January 16, CCADD was selected as the lead research institution for the 2025 Contract Research and Development Project by the Ministry of Food and Drug Safety (MFDS). The project aims to develop a large-scale Korean-English corpus and translation model specialized in the pharmaceutical field. The total research funding amounts to KRW 1 billion (approximately USD 692,900). For this project, CCADD will collaborate with the Structure & Knowledge Injection into Machine Learning lab (SKIML) at the Graduate School of Data Science, Seoul National University (PI: Prof. Jaeyoon Lee) and the Korea Regulatory Science Center (PI: Dr. Sungkoo Son).

As part of this research, the team will develop a high-quality, domain-specific Korean-English corpus, ensuring consistent translation quality. The corpus will be rigorously validated and evaluated by experts to maintain translation accuracy and reliability. Furthermore, the team will develop a -level Korean-English neural machine translation (NMT) model and a large language model (LLM) in the pharmaceutical and medical fields based on this corpus.

CCADD and its research team officially launched the project with an initiation meeting on February 13 with MFDS. During the meeting, key stakeholders established research objectives and outlined a strategic roadmap for the next two years.

The team members, David Seung U Lee, Yujin Kim, and Prof. Howard Lee anticipate this research will establish Korea’s first high-quality pharmaceutical corpus and develop an advanced translation model processing pharmaceutical information accurately. With expertise in regulatory science, drug development, and AI, CCADD aims to successfully complete the project and contribute to advancements in pharmaceutical and medical fields.